Topiramate is an anticonvulsant licensed in the UK for epilepsy and migraine prevention, and although weight loss can occur as a side effect, it is not licensed for weight management and carries significant neurological, metabolic, and pregnancy-related risks
Store in a cool, dry, secure and sterile environment away from any unauthorised persons or children.
Stress management skills, neuroimmune processes and fatigue levels in persons with chronic fatigue syndrome
Key Takeaways: Semaglutide is the active ingredient in both Ozempic and Wegovy, working by mimicking GLP-1 to reduce appetite and improve blood sugar control. Wegovy (higher-dose semaglutide) is FDA-approved for weight loss, while Ozempic is primarily approved for type 2 diabetes but often used off-label. Clinical trials show semaglutide can lead to ~15% body weight loss over ~68 weeks when combined with lifestyle changes. Ozempic typically produces slightly lower average weight loss due to its lower maximum dose, though results can still be significant. Gradual tapering off semaglutide, combined with lifestyle support, may help reduce weight regain after stopping treatment. Long-term success depends on pairing medication with nutrition, physical activity, and ongoing medical guidance. Understanding the Basics Semaglutide is the active drug found in both Ozempic and Wegovy
